Report cover image

Global Rifaximin Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 195 Pages
SKU # APRC20557518

Description

Summary

According to APO Research, the global Rifaximin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Rifaximin market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Rifaximin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Rifaximin market include Texas Pharmaceuticals, STERIS PHARMA, Soigner Pharma, Salix Pharmaceuticals and Cassopeia Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Rifaximin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Rifaximin, also provides the sales of main regions and countries. Of the upcoming market potential for Rifaximin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rifaximin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Rifaximin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Rifaximin sales, projected growth trends, production technology, application and end-user industry.

Rifaximin Segment by Company

Texas Pharmaceuticals
STERIS PHARMA
Soigner Pharma
Salix Pharmaceuticals
Cassopeia Pharmaceuticals
Rifaximin Segment by Type

200 mg Tablets
550 mg Tablets
Rifaximin Segment by Application

Hospital
Drug store
Rifaximin Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Rifaximin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Rifaximin market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Rifaximin significant trends, drivers, influence factors in global and regions.
6. To analyze Rifaximin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rifaximin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rifaximin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rifaximin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rifaximin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rifaximin industry.
Chapter 3: Detailed analysis of Rifaximin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Rifaximin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Rifaximin in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

195 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Rifaximin Sales Value (2020-2031)
1.2.2 Global Rifaximin Sales Volume (2020-2031)
1.2.3 Global Rifaximin Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Rifaximin Market Dynamics
2.1 Rifaximin Industry Trends
2.2 Rifaximin Industry Drivers
2.3 Rifaximin Industry Opportunities and Challenges
2.4 Rifaximin Industry Restraints
3 Rifaximin Market by Company
3.1 Global Rifaximin Company Revenue Ranking in 2024
3.2 Global Rifaximin Revenue by Company (2020-2025)
3.3 Global Rifaximin Sales Volume by Company (2020-2025)
3.4 Global Rifaximin Average Price by Company (2020-2025)
3.5 Global Rifaximin Company Ranking (2023-2025)
3.6 Global Rifaximin Company Manufacturing Base and Headquarters
3.7 Global Rifaximin Company Product Type and Application
3.8 Global Rifaximin Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Rifaximin Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Rifaximin Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Rifaximin Market by Type
4.1 Rifaximin Type Introduction
4.1.1 200 mg Tablets
4.1.2 550 mg Tablets
4.2 Global Rifaximin Sales Volume by Type
4.2.1 Global Rifaximin Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Rifaximin Sales Volume by Type (2020-2031)
4.2.3 Global Rifaximin Sales Volume Share by Type (2020-2031)
4.3 Global Rifaximin Sales Value by Type
4.3.1 Global Rifaximin Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Rifaximin Sales Value by Type (2020-2031)
4.3.3 Global Rifaximin Sales Value Share by Type (2020-2031)
5 Rifaximin Market by Application
5.1 Rifaximin Application Introduction
5.1.1 Hospital
5.1.2 Drug store
5.2 Global Rifaximin Sales Volume by Application
5.2.1 Global Rifaximin Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Rifaximin Sales Volume by Application (2020-2031)
5.2.3 Global Rifaximin Sales Volume Share by Application (2020-2031)
5.3 Global Rifaximin Sales Value by Application
5.3.1 Global Rifaximin Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Rifaximin Sales Value by Application (2020-2031)
5.3.3 Global Rifaximin Sales Value Share by Application (2020-2031)
6 Rifaximin Regional Sales and Value Analysis
6.1 Global Rifaximin Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Rifaximin Sales by Region (2020-2031)
6.2.1 Global Rifaximin Sales by Region: 2020-2025
6.2.2 Global Rifaximin Sales by Region (2026-2031)
6.3 Global Rifaximin Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Rifaximin Sales Value by Region (2020-2031)
6.4.1 Global Rifaximin Sales Value by Region: 2020-2025
6.4.2 Global Rifaximin Sales Value by Region (2026-2031)
6.5 Global Rifaximin Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Rifaximin Sales Value (2020-2031)
6.6.2 North America Rifaximin Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Rifaximin Sales Value (2020-2031)
6.7.2 Europe Rifaximin Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Rifaximin Sales Value (2020-2031)
6.8.2 Asia-Pacific Rifaximin Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Rifaximin Sales Value (2020-2031)
6.9.2 South America Rifaximin Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Rifaximin Sales Value (2020-2031)
6.10.2 Middle East & Africa Rifaximin Sales Value Share by Country, 2024 VS 2031
7 Rifaximin Country-level Sales and Value Analysis
7.1 Global Rifaximin Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Rifaximin Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Rifaximin Sales by Country (2020-2031)
7.3.1 Global Rifaximin Sales by Country (2020-2025)
7.3.2 Global Rifaximin Sales by Country (2026-2031)
7.4 Global Rifaximin Sales Value by Country (2020-2031)
7.4.1 Global Rifaximin Sales Value by Country (2020-2025)
7.4.2 Global Rifaximin Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Rifaximin Sales Value Growth Rate (2020-2031)
7.5.2 USA Rifaximin Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Rifaximin Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Rifaximin Sales Value Growth Rate (2020-2031)
7.6.2 Canada Rifaximin Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Rifaximin Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Rifaximin Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Rifaximin Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Rifaximin Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Rifaximin Sales Value Growth Rate (2020-2031)
7.8.2 Germany Rifaximin Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Rifaximin Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Rifaximin Sales Value Growth Rate (2020-2031)
7.9.2 France Rifaximin Sales Value Share by Type, 2024 VS 2031
7.9.3 France Rifaximin Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Rifaximin Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Rifaximin Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Rifaximin Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Rifaximin Sales Value Growth Rate (2020-2031)
7.11.2 Italy Rifaximin Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Rifaximin Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Rifaximin Sales Value Growth Rate (2020-2031)
7.12.2 Spain Rifaximin Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Rifaximin Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Rifaximin Sales Value Growth Rate (2020-2031)
7.13.2 Russia Rifaximin Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Rifaximin Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Rifaximin Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Rifaximin Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Rifaximin Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Rifaximin Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Rifaximin Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Rifaximin Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Rifaximin Sales Value Growth Rate (2020-2031)
7.16.2 China Rifaximin Sales Value Share by Type, 2024 VS 2031
7.16.3 China Rifaximin Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Rifaximin Sales Value Growth Rate (2020-2031)
7.17.2 Japan Rifaximin Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Rifaximin Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Rifaximin Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Rifaximin Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Rifaximin Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Rifaximin Sales Value Growth Rate (2020-2031)
7.19.2 India Rifaximin Sales Value Share by Type, 2024 VS 2031
7.19.3 India Rifaximin Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Rifaximin Sales Value Growth Rate (2020-2031)
7.20.2 Australia Rifaximin Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Rifaximin Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Rifaximin Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Rifaximin Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Rifaximin Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Rifaximin Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Rifaximin Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Rifaximin Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Rifaximin Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Rifaximin Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Rifaximin Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Rifaximin Sales Value Growth Rate (2020-2031)
7.24.2 Chile Rifaximin Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Rifaximin Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Rifaximin Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Rifaximin Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Rifaximin Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Rifaximin Sales Value Growth Rate (2020-2031)
7.26.2 Peru Rifaximin Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Rifaximin Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Rifaximin Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Rifaximin Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Rifaximin Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Rifaximin Sales Value Growth Rate (2020-2031)
7.28.2 Israel Rifaximin Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Rifaximin Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Rifaximin Sales Value Growth Rate (2020-2031)
7.29.2 UAE Rifaximin Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Rifaximin Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Rifaximin Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Rifaximin Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Rifaximin Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Rifaximin Sales Value Growth Rate (2020-2031)
7.31.2 Iran Rifaximin Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Rifaximin Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Rifaximin Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Rifaximin Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Rifaximin Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Texas Pharmaceuticals
8.1.1 Texas Pharmaceuticals Comapny Information
8.1.2 Texas Pharmaceuticals Business Overview
8.1.3 Texas Pharmaceuticals Rifaximin Sales, Value and Gross Margin (2020-2025)
8.1.4 Texas Pharmaceuticals Rifaximin Product Portfolio
8.1.5 Texas Pharmaceuticals Recent Developments
8.2 STERIS PHARMA
8.2.1 STERIS PHARMA Comapny Information
8.2.2 STERIS PHARMA Business Overview
8.2.3 STERIS PHARMA Rifaximin Sales, Value and Gross Margin (2020-2025)
8.2.4 STERIS PHARMA Rifaximin Product Portfolio
8.2.5 STERIS PHARMA Recent Developments
8.3 Soigner Pharma
8.3.1 Soigner Pharma Comapny Information
8.3.2 Soigner Pharma Business Overview
8.3.3 Soigner Pharma Rifaximin Sales, Value and Gross Margin (2020-2025)
8.3.4 Soigner Pharma Rifaximin Product Portfolio
8.3.5 Soigner Pharma Recent Developments
8.4 Salix Pharmaceuticals
8.4.1 Salix Pharmaceuticals Comapny Information
8.4.2 Salix Pharmaceuticals Business Overview
8.4.3 Salix Pharmaceuticals Rifaximin Sales, Value and Gross Margin (2020-2025)
8.4.4 Salix Pharmaceuticals Rifaximin Product Portfolio
8.4.5 Salix Pharmaceuticals Recent Developments
8.5 Cassopeia Pharmaceuticals
8.5.1 Cassopeia Pharmaceuticals Comapny Information
8.5.2 Cassopeia Pharmaceuticals Business Overview
8.5.3 Cassopeia Pharmaceuticals Rifaximin Sales, Value and Gross Margin (2020-2025)
8.5.4 Cassopeia Pharmaceuticals Rifaximin Product Portfolio
8.5.5 Cassopeia Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Rifaximin Value Chain Analysis
9.1.1 Rifaximin Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Rifaximin Sales Mode & Process
9.2 Rifaximin Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Rifaximin Distributors
9.2.3 Rifaximin Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.